Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis

Alimentary Pharmacology and Therapeutics Symposium Series

Volumn 2, Issue 1, 2006, Pages 147-152

  Watanabe, K ^a   Oshitani, N ^a   Kamata, N ^a   Inagawa, M ^a   Yamagami, H ^a   Higuchi, K ^a   Arakawa, T ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; COLON MUCOSA; COLON ULCER; COLONOSCOPY; CONFERENCE PAPER; CYTAPHERESIS; DRUG DEPENDENCE; FEMALE; GRANULOCYTE AND MONOCYTE ADSORPTION APHERESIS; HEADACHE; HUMAN; LEUKAPHERESIS; MALE; PRIORITY JOURNAL; STEROID THERAPY; THERAPY EFFECT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 34247868877     PISSN: 17466334     EISSN: 17466342     Source Type: Journal    
DOI: 10.1111/j.1746-6342.2006.00038.x     Document Type: Conference Paper

References (34)

1. Truelove SC, Jewell DP. Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet 1974 1:1067 70.
2. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: A prospective, randomized, double-blind clinical trial. Gastroenterology 1983 85:351 7.
3. Jarnerot G, Rolyny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985 89:1005 13.
4. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000 6:48 57.
5. Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003 9:307 21.
6. Sawada K, Shimoyama T. Therapeutic cytapheresis for inflammatory bowel disease. Ther Apher 1998 2:90 2.
7. Yajima T, Takahashi H, Kanai T, et al. Predictive factors of response to leukocytapheresis therapy for ulcerative colitis. Ther Apher 1998 2:115 9.
8. Sasaki M, Tsujikawa T, Fujiyama Y, et al. Leukocytapheresis therapy for severe ulcerative colitis. Ther Apher 1998 2:101 4.
9. Noguchi M, Hiwatashi N, Hayakawa T, et al. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: Role of bystander suppression. Ther Apher 1998 2:109 14.
10. Nagase K, Sawada K, Ohnishi K, et al. Complications of leukocytapheresis. Ther Apher 1998 2:120 4.
11. Hanai H, Watanabe F, Saniabadi AR, et al. Therapeutic efficacy of granulocyte and monocyte absorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002 47:2349 53.
12. Fukunaga K, Fukuda Y, Sawada K, et al. Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy. J Gastroenterol 2003 38:684 9.
13. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003 1:28 35.
14. Premchand P, Takeuchi K, Bjarnason I. Granulocyte, macrophage, monocyte apheresis for refractory ulcerative colitis. Eur J Gastroenterol Hepatol 2004 16:943 5.
15. Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004 10:251 7.
16. Yamamoto T, Umegae S, Kitagawa T, et al. Granulocyte and monocyte adaptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 2004 20:783 92.
17. Doménech E, Hinojosa J, Esteve-comas M, et al. Granulocyte apheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004 20:1347 52.
18. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004 70:36 44.
19. Suzuki Y, Yoshimura N, Saniabadi AR, et al. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004 49:565 71.
20. Kanke K, Nakano M, Hirahashi H, et al. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 2004 36:811 17.
21. Matsui T, Nishimura T, Matake H, et al. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2003 98:511 12.
22. Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002 97:2820 8.
23. Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory disease associated with leukocytes. Ther Apher Dial 2003 7:48 59.
24. Kawagishi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte absorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002 47:1334 41.
25. Takeda Y, Hiraishi K, Takeda H, et al. Cellulose acetate beads induce release of interleukin-1 receptor antagonist, but not tumor necrosis factor-α or interleukin-1β in human peripheral blood. Inflamm Res 2003 52:287 90.
26. Hiraishi K, Takeda Y, Shiobara N, et al. Studies on the mechanism of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003 7:334 40.
27. Nagase K, Fukunaga K, Ohnishi K, et al. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant. Ther Apher Dial 2004 8:45 51.
28. Ando A, Ogawa A, Kitamura K, et al. Suppression of interleukin-1β- and tumor necrosis factor-α-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004 39:1150 7.
29. Ogata H, Matsui T, Nakamura M, et al. A randomised, dose-finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 Epub ahead of print D. Coated mesalamine (5-amino-salicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989 298:82 6.
30. Robert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003 52:998 1002.
31. Ross AS, Cohen RD. Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep 2004 6:488 95.
32. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003 98:2372 82.
33. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2007 17:135 9.
34. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001 16:1 9.